Table 3:
Binary test results based on cut-off determination for PHI and PHID in NFUS and FUS prostate biopsies.
| Non-Fused Biopsies | |||
|---|---|---|---|
| Cut-off based on | Youden J index | Sensitivity = 95% | Sensitivity = 100% |
| PHI cut-off value | 45.9 | 24.7 | 21.0 |
| PHI Test positive/biopsy positive | 24 (GG1=7, ≥GG2=17) | 31 (GG1=11, ≥GG2=20) | 33 (GG1=12, ≥GG2=21) |
| PHI Test negative/biopsy positive | 9 (GG1=5, ≥GG2=4) | 2 (GG1=1, ≥GG2=1) | 0 |
| PHI Test positive/biopsy negative | 20 | 71 | 84 |
| PHI Test negative/biopsy negative | 68 | 17 | 4 |
| Sensitivity (%) | 73 (54 to 87) | 94 (80 to 99) | 100 (89 to 100) |
| Specificity (%) | 77 (67 to 86) | 19 (12 to 29) | 4 (1 to 11) |
| Positive Predictive Value (%) | 54 (42 to 74) | 30 (22 to 41) | 28 (20 to 37) |
| Negative Predictive Value (%) | 88 (77 to 93) | 89 (67 to 98) | 100 (39 to 100) |
| Fused Biopsies | |||
| PHID cut-off value | 0.64 | 0.52 | 0.32 |
| PHID Test positive/biopsy positive | 43 (GG1=13, ≥GG2=30) | 47 (GG1=15, ≥GG2=32) | 49 (GG1=16, ≥GG2=33) |
| PHID Test negative/biopsy positive | 6 (GG1=3, ≥GG2=3) | 2 (GG1=1, ≥GG2=1) | 0 |
| PHID Test positive/biopsy negative | 15 | 22 | 35 |
| PHID Test negative/biopsy negative | 26 | 19 | 6 |
| Sensitivity (%) | 88 (75 to 95) | 96 (86 to 99) | 100 (93 to 100) |
| Specificity (%) | 63 (47 to 78) | 46 (31 to 63) | 15 (5 to 29) |
| Positive Predictive Value (%) | 74 (61 to 85) | 68 (56 to 79) | 58 (47 to 69) |
| Negative Predictive Value (%) | 81 (63 to 93) | 90 (70 to 99) | 100 (54 to 100) |
Data presented as counts or estimate (95% CI).